Bioxcel therapeutics announces positive findings from independent third party audit of data integrity at tranquility ii phase 3 trial site

No evidence of misconduct or fraud found beyond instance previously reported 1 no findings identified that impact data integrity company believes audit findings support reliability of positive tranquility ii trial data and potential snda submission new haven, conn., oct. 25, 2023 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced positive findings from an independent third party audit of the data from a single site1 in its tranquility ii phase 3 trial.
BTAI Ratings Summary
BTAI Quant Ranking